IMPERIAL Data Sheet
View the remarkable results Eluvia achieved in the first head-to-head trial: Eluvia DES vs. Zilver PTX.
IMPERIAL Long Lesion Sub-Study Data Sheet
Learn more about the 87.9% primary patency Eluvia demonstrated in the IMPERIAL long lesion sub-study (162.8 mm lesion length).
IMPERIAL Diabetic Subgroup Analysis Data Sheet
Learn more about the statistically significant difference in TLR Eluvia demonstrated in the IMPERIAL Diabetic Subgroup Analysis.
New data from the IMPERIAL trial
Eluvia is more effective in diabetic patients.
Dr. William Gray: IMPERIAL Trial
Hear the full IMPERIAL Trial presentation from the Principal Investigator, William Gray, MD.
Münster All-Comers Registry
Expert Panel Discussion
Hear in-depth commentary on IMPERIAL, the first head-to-head DES SFA Trial, including key insights and perspectives on how the data will impact treatment of PAD patients.
Moving Forward with Drug Eluting Technologies
During CIRSE 2019, a panel of experts discussed the latest on delivery of paclitaxel and available datasets from Drug Eluting devices for PAD.
IMPERIAL Trial: First of its Kind Design
Physicians provide an overview of the trial’s unique design, including the Eluvia DES and how investigators sought to improve on prior technologies.
IMPERIAL Trial Overview
Hear a panel of physicians discuss IMPERIAL’s efficacy and safety results and how they change the landscape of clinical trials.
What's Unique about the IMPERIAL Trial?
Experts share their perspectives on what IMPERIAL’s Kaplan-Meier Primary Patency curves tell them about durability and lack of need for reintervention.
Impact of the IMPERIAL Trial
Hear physician commentary on how the IMPERIAL Trial’s level 1 evidence is influencing their clinical and economic decisions.
Eluvia DES: A More Durable Result for Patients
Physicians discuss the IMPERIAL Trial from a patient perspective and share how the Eluvia stent may provide a more durable result.
IMPERIAL Trial: Influencing Treatment Algorithms
See how IMPERIAL Trial results may help physicians make recommendations on which forms of antiproliferative therapies are best for each patient.
Hear what physicians have to say about the challenges of treating the SFA and how drug-eluting stents may help improve patient outcomes.
Physicians talk about the importance of drug-eluting stents in complex lesions and how the Eluvia Drug-Eluting Stent is fine-tuned to produce a sustainable release of paclitaxel over time.
See how over a decade of research helped Eluvia engineers develop the first drug-eluting stent for the SFA designed to sustain drug release when restenosis is most likely.
See what physicians are saying about the unprecedented clinical outcomes for the Eluvia Drug-Eluting Stent, including two-year primary patency and TLR rates.
Following the meta-analysis, Pr. Vermassen talks about his current practice and best options to treat challenging lesions.
The Challenges of the SFA
Find out how the challenging biological environment, mechanical issues and timing of disease progression impact treatment of the SFA.
The Design of the Eluvia Drug-Eluting Stent System
Discover how the Eluvia Drug-Eluting Stent was designed to match the restenotic cascade for better healing and patency in the superficial femoral arteries (SFA).
UPN & GTIN
Eluvia UPN and GTIN
Download Eluvia Drug-Eluting Stent U.S. UPN & GTIN.
Eluvia on White
Download an image of the Eluvia Drug-Eluting Vascular Stent System on a white background to use in press materials and more.
Eluvia on Black
Download an image of the Eluvia Drug-Eluting Vascular Stent System on a black background to use in press materials and more.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.